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Abstract
Purpose—Cancer stem cells (CSCs) are thought to be responsible for tumor progression, 
metastasis, and recurrence. HER2 overexpression is associated with increased CSCs, which may 
explain the aggressive phenotype and increased likelihood of recurrence for HER2+ breast 
cancers. Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in 
normal tissues, providing potential for telomerase inhibition in anti-cancer therapy. The purpose of 
this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat 
(GRN163L), on CSC and non-CSC populations of HER2+ breast cancer cell lines.
Methods—The effects of imetelstat on CSC populations of HER2+ breast cancer cells were 
measured by ALDH activity and CD44/24 expression by flow cytometry as well as mammosphere 
assays for functionality. Combination studies in vitro and in vivo were utilized to test for 
synergism between imetelstat and trastuzumab.
Results—Imetelstat inhibited telomerase activity in both subpopulations. Moreover, imetelstat 
alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC 
functional ability, as shown by decreased mammosphere counts and invasive potential. Tumor 
growth rate was slower in combination treated mice compared to either drug alone. Additionally, 
there was a trend toward decreased CSC marker expression in imetelstat treated xenograft cells 
compared to vehicle control. Furthermore, the observed decrease in CSC marker expression 
occurred prior to and after telomere shortening, suggesting imetelstat acts on the CSC 
subpopulation in telomere length independent and dependent mechanisms.
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Conclusions—Our study suggests addition of imetelstat to trastuzumab may enhance the effects 
of HER2 inhibition therapy, especially in the CSC population.
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INTRODUCTION
The cancer stem cell (CSC) hypothesis postulates that many cancers, including breast 
cancer, are hierarchically organized and a subpopulation of cells within the tumor possess 
the basic properties of stem cells, the ability to self-renew and differentiate [1,2]. CSCs also 
have other stem cell-like properties including the active expression of telomerase, anti-
apoptotic pathway activation, increased activity of membrane transporters, and an increased 
ability to migrate [3]. Evidence suggests that CSCs may be responsible for tumor 
progression, metastasis, chemotherapy and radiotherapy resistance, and subsequent tumor 
recurrence [4-8]. Breast CSCs can be identified using the cell surface marker expression 
CD44+/CD24− or elevated enzymatic activity of aldehyde dehydrogenase (ALDH) [1,9].
Multiple studies suggest Human Epidermal Growth Factor Receptor 2 (HER2) plays an 
important role in regulating the CSC population in HER2+ breast cancer. HER2 
overexpression and ALDH expression are significantly correlated in human breast cancer 
patient samples [9]. The CSC subpopulation in HER2 overexpressing breast cancer cell lines 
expresses the highest levels of HER2 protein without HER2 gene amplification changes 
[10]. Additionally, HER2 overexpression expands the normal breast epithelial stem/early 
progenitor cell population, as well as the CSC population in malignant breast cells, resulting 
in increased tumorigenicity and invasiveness with HER2 amplification [11]. HER2 blockade 
via trastuzumab or HER2/EGFR blockade via lapatinib decreases the CSC population 
[10,11]. Neoadjuvant trastuzumab significantly increases pathologic complete response rate 
compared to chemotherapy alone, suggesting a reduction in the CSC population [12,13]. In 
contrast to chemotherapy, lapatinib reduced the CSC population in the neoadjuvant setting, 
although this decrease was not statistically significant [7].
A hallmark of the cancer cell is its limitless replicative potential, achieved almost 
exclusively by telomere maintenance via telomerase reactivation [14]. Telomerase, the 
reverse transcriptase enzyme, is absent or lowly expressed in most normal somatic cells, but 
is highly expressed in cancer and enables malignant cells to maintain their telomere length 
just above the critically short threshold and thereby avoid senescence and apoptosis [15-18]. 
The differential expression between normal cells and cancer cells and the shorter telomere 
length of cancer cells makes telomerase inhibition a striking target for potential cancer 
therapeutics [19]. This potential led to the development of imetelstat (GRN163L), a 
lipidated 13-mer oligonucleotide N3′→P5′ thio phosphoramidate [20,21]. Imetelstat binds 
with high affinity to the template region of the RNA component of human telomerase 
resulting in competitive inhibition of telomerase enzymatic activity [22,23]. Our group and 
others have shown imetelstat alone, and in combination with chemotherapeutic agents or 
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irradiation, can inhibit telomerase in a variety of tumor cells and compromise cancer cell 
viability and growth, both in vitro and in vivo [24-32].
Telomerase is expressed in both bulk cancer cells and CSCs, suggesting CSCs could be 
sensitive to telomerase inhibition therapy [6,33]. Imetelstat has been shown to target the 
CSC population in a number of tumor types [34-37]. While these studies investigated 
changes in marker expression, spheroid formation, and tumor growth in vivo after imetelstat 
pretreatment, the effect of telomerase inhibition on invasion and metastases was not 
addressed nor the effect of imetelstat in combination with standard therapies on the CSC 
population. Telomerase inhibitors are most effective when used in combination, likely due 
to the long lag time to achieve telomere shortening [38]. Our laboratory has shown 
imetelstat can augment the effects of trastuzumab and restore sensitivity in trastuzumab-
resistant breast cancer cell lines [27].
In this study, we investigated the effect of imetelstat and trastuzumab treatment in HER2+ 
breast cancer cell lines. CSCs have active telomerase that can be inhibited by imetelstat 
treatment. Imetelstat alone can decrease the percentage of CSCs, as well as inhibit 
mammosphere formation. Additionally, we found imetelstat and trastuzumab combination 
treatment decreases the CSC population, mammosphere formation, invasive potential, and 
tumor growth in vivo.
MATERIALS AND METHODS
Reagents
The telomerase template antagonist, Imetelstat (GRN163L, 5'-Palm-TAGGGTTAGACAA-
NH2-3'), and its complimentary control oligonucleotide with the same chemistry (Sense, 5'-
Palm-ATCCAATCTGTT-NH2-3') were provided by Geron Corp and were prepared as 
previously described [23]. Trastuzumab was provided by the Indiana University Simon 
Cancer Center (IUSCC) Infusion Pharmacy.
Cell Culture
HCC1569 and HCC1954 breast cancer cell lines were purchased from ATCC (CRL-2330 
and CRL-2338) and cultured in RPMI media (Corning cellgro) containing 10% fetal bovine 
serum (FBS, Fisher Scientific). SKBR3 and trastuzumab-resistant SKBR3-R pool 1 cells 
were a gift from Dr. Francisco Esteva (MD Anderson Cancer Center) and were cultured in 
DMEM/F12 media containing 10% FBS. Resistant cells (SKBR3-R) were cultured with the 
addition of 4 µg/mL trastuzumab [39]. TMD-231 cells were a gift from Dr. Harikrishna 
Nakshatri (Indiana University School of Medicine) [40] and were cultured in DMEM media 
containing 10% FBS.
Treatment with Imetelstat and/or Trastuzumab
Cells were allowed to attach overnight prior to drug treatment. To refresh imetelstat, media 
was spiked with imetelstat every 3 days and all cells were counted and passaged every 6-7 
days. For the CSC marker expression studies, cells were treated with 2.5 µM imetelstat 
and/or trastuzumab [0.625 µM (1 trastuzumab: 4 imetelstat) for HCC1954 and SKBR3 cells 
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and 0.3125 µM (1 trastuzumab: 8 imetelstat) for HCC1569 cells]. For the cell sorting 
experiments, cells were treated with 2.5 µM imetelstat or sense oligonucleotide for 3 days 
for telomerase activity and 6 weeks for telomere length.
Flow Cytometry and Fluorescence Activated Cell Sorting (FACS)
Flow cytometric analysis was performed using an LSRII 407 nm laser cytometer (BD 
Biosciences) and cell sorting using a Special Order Research Product FACSAria sorter (BD 
Biosciences). Cells were stained with APC-H7-conjugated CD44, PE-Cy7- conjugated 
CD24, and violet LIVE/DEAD fixable cell stain (all antibodies from BD Biosciences and 
viability stain from Life Technologies). FMO (fluorescence minus one) controls were used 
to determine appropriate gates. The Aldefluor assay was used to measure and separate cells 
based on ALDH activity according to manufacturer’s guidelines (StemCell Technologies). 
Control samples treated with DEAB (diethylaminobenzaldehyde) were used for gating the 
negative population. FlowJo software was used for all analyses.
Methods for telomerase activity and telomere length determination, methylene blue cell 
proliferation for combination studies, mammosphere cultures, invasion assays, xenograft 
animal studies, and statistical analyses are available in supplemental information.
RESULTS
Long term treatment with imetelstat inhibits cell growth
To study the effects of imetelstat treatment in HER2+ breast cancer cell lines, we first 
measured cumulative population doublings in two HER2+ cell lines not previously studied 
for telomerase inhibition, HCC1569 and HCC1954. Cumulative population doublings of the 
HCC1569 and HCC1954 cell lines statistically significantly differed between imetelstat and 
untreated cells at the time point indicated by the arrow and remained different throughout 
the remainder of the experiment (Fig, S1, two-way repeated measures ANOVA, p < 0.05). 
HCC1569 cells stopped doubling and reached the stationary phase or plateau of the 
population doubling graph after 17 weeks of treatment. HCC1954 reached the stationary 
phase after 10 weeks of treatment. The sense oligonucleotide control had a minor effect on 
cell proliferation, but it occurred much later than imetelstat and did not inhibit cells from 
continuing to proliferate. Although cumulative population doublings began to differ sooner 
in the HCC1569 cells, it took longer to reach the plateau than in HCC1954 cells. The 
HCC1569 cells were slower growing, doubling about 4 times per week versus 5 times in the 
HCC1954, and have longer baseline telomere length, which may explain why a longer 
treatment regimen is required to reach the stationary phase in this cell line.
HER2+ CSCs have active telomerase and are sensitive to telomerase inhibition via 
imetelstat
Previous studies have reported similar telomerase activity between CSCs and their bulk 
tumor cell counterparts, as well as similarities in telomere length [35,6]. We determined 
whether our HER2+ cell lines also had similar telomerase activity and telomere length in the 
CSC, non-CSC (bulk tumor cells), and unsorted populations. HCC1569 cell line was flow 
sorted based on either CD44/CD24 expression or ALDH enzymatic activity. Unsorted, non-
Koziel and Herbert Page 4
Breast Cancer Res Treat. Author manuscript; available in PMC 2016 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CSC, and CSC populations all had active telomerase (Fig. 1a-b). There was no difference in 
relative telomerase activity between CSC, non-CSC, and unsorted cells in the HCC1569 cell 
line based on CD44/CD24 expression (Fig. 1b, one-way ANOVA, p > 0.05 for untreated, 
sense, and imetelstat groups). We also tested whether imetelstat can inhibit telomerase 
activity in the different subpopulations. Imetelstat (163L) was able to abolish telomerase 
activity in both the CSC and non-CSC populations; however, as expected, the sense 
oligonucleotide control did not affect telomerase activity (Fig. 1a-b). ALDH enzymatic 
activity was used to sort the HCC1954 cell line, as well as another HER2+ breast cancer cell 
line we have previously used for telomerase inhibition studies, the SKBR3 cell line [27]. 
Again, we found unsorted, non-CSC, and CSC populations had active telomerase that 
imetelstat was able to inhibit in both subpopulations (Fig. 1c-d). In line with the previous 
reports, we found similar average telomere length between the CSC and non-CSC 
populations in our HER2+ breast cancer cell lines (Fig. 1e, S2). Six weeks of imetelstat 
treatment decreased average telomere length in the HCC1954 cell line, but not the HCC1569 
cell line (Fig. 1e, S2). HCC1569 cells had a longer baseline telomere length than HCC1954, 
possibly explaining why we did not see differences in average telomere length at this time 
point of treatment. However, there appeared to be a shortening of longer telomeres in both 
cell lines with imetelstat treatment, shown by a shift downward in the telomere smear (Fig. 
1e). Indeed, examination of the densitometry of the telomere smears revealed shortening of 
longer telomeres with imetelstat treatment, shown by a shift in the curve toward a smaller 
molecular weight (Fig. 1f).
Telomerase inhibition can decrease CSCs and limit mammosphere formation
The use of breast cancer cell lines to study CSCs has been validated [41,42]. SKBR3, 
HCC1954, and HCC1569 cell lines were subjected to flow cytometry analysis of CD44/
CD24 marker expression and ALDH enzymatic activity. The HCC1569 cell line was 
positive for CD44 expression and contained positive and negative CD24 expressing cells, 
allowing us to use this cell line to measure the CD44+/CD24− CSC population (Fig. S3a). 
Both HCC1954 and SKBR3 cell lines did not have a measureable CD44+/CD24− population 
(Fig. S3b-c). As predicted by the correlation of HER2 and ALDH, all three cell lines had 
ALDH+ CSC subpopulations [9].
To determine the effect of telomerase inhibition on the CSC population, we measured 
CD44+/CD24− expression in the HCC1569 cell line. Long-term treatment with imetelstat 
decreased the CSC population by more than twenty percent, whereas the sense 
oligonucleotide control had no effect on the CSC population (Fig. 2a-b). Furthermore, 
imetelstat pretreatment significantly decreased mammosphere count, an in vitro assessment 
of stem cell function, compared to untreated and sense controls (Fig. 2c-e, one-way 
ANOVA, p < 0.05).
Imetelstat augments the effects of trastuzumab in HER2+ breast cancer cell lines
Our lab has previously reported a synergistic effect of imetelstat and trastuzumab 
combination therapy in vitro [27]. We next verified this effect applied to the HCC1569 and 
HCC1954 cell lines, which have previously been classified as having a de novo resistance to 
trastuzumab [43]. IC50 values of trastuzumab and imetelstat were determined for both cell 
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lines and used to select drug ratios for combination treatments. Trastuzumab and imetelstat 
combination shifted the dose-response curve and significantly decreased the concentration 
of both drugs needed to achieve the IC50 (Fig. 3). Moreover, the combination index showed 
a synergistic effect (CI < 1) at most concentrations tested (Table 1). Although these cells are 
reported to be innately resistant to trastuzumab and we did notice little effect on cell 
proliferation at lower concentrations, we were able to determine IC50 values and showed 
combination treatment decreased the IC50 value for both trastuzumab and imetelstat. These 
combination studies suggest imetelstat can augment the effects of trastuzumab.
Imetelstat in combination with trastuzumab decreases the CSC population
We next wanted to determine the effect of imetelstat and trastuzumab combination treatment 
on the CSC population. In accordance with Fig. 2, we found imetelstat alone was able to 
decrease the CSC population (Fig. 4a-c, green bars). Although trastuzumab alone did not 
affect the percentage of CD44+/CD24− CSCs (Fig. 4a, red bars), we found trastuzumab 
decreased the ALDH+ CSC population (Fig. 4b-c, red bars) as previously published [10,11]. 
Combination treatment significantly decreased the CD44+/CD24− CSC population in the 
HCC1569 cell line (p < 0.05 for 12-54 days of treatment) (Fig. 4a, purple bars). Moreover, 
combination treatment decreased the ALDH+ CSC population in all cell lines tested, 
although statistical analyses is hindered due to high variability of enzymatic activity (Fig. 
4b-c, purple bars).
We next wanted to determine if the decrease in the CSC population after combination 
treatment resulted in decreased functional ability of the CSCs. We observed a significant 
decrease in mammosphere count and smaller spheroids following trastuzumab, imetelstat, 
and combination treatment after short term (12 days) and long term (90 days) pretreatment, 
suggesting CSC self-renewal is continually inhibited by these agents (Fig. 5a-b). Moreover, 
short term treatment with imetelstat may not lead to telomere shortening, but long term 
treatment certainly does, suggesting imetelstat may inhibit the self-renewal potential of 
CSCs in telomere length dependent and independent mechanisms. It has been reported that 
the CSC population has an increased invasive potential, an early step required for metastasis 
[44,41]. We performed invasion assays to determine if the decrease in CSCs following 
imetelstat and/or trastuzumab treatment correlated with decreased invasive potential. Twelve 
day imetelstat and combination treatments significantly decreased the invasive potential 
compared to untreated samples, with less than half as many cells invading (Fig. 5c-d).
Imetelstat and trastuzumab combination treatment decreases primary tumor growth in 
vivo
We and others have shown imetelstat treatment can decrease primary tumor growth in 
xenograft mouse models [24,28,30,31]. However, the effect of imetelstat and trastuzumab 
combination treatment on xenograft tumor growth has not previously been studied. We 
found a significant decrease in primary tumor growth of HCC1954 cells implanted into the 
mammary fat pad of NSG mice and then treated with combination of imetelstat and 
trastuzumab (Fig. 6a). However, the study was concluded, due to burdensome tumor volume 
in the vehicle control group, before differences in tumor volume between the trastuzumab 
alone and combination group could be observed. Tumor growth rates, calculated as the slope 
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of the line of tumor volume versus days post inoculation, appeared to be different between 
combination and trastuzumab alone groups, suggesting addition of imetelstat can enhance 
the effects of trastuzumab on tumor growth (Fig. 6b). HCC1954 cells did not reliably 
metastasize following tertiary passaging in mice (data not shown); therefore, we studied the 
effect of imetelstat alone in a triple negative breast cancer cell line, TMD-231 [45]. The 
primary tumor tissue from this study was digested to generate a single cell suspension, 
which were then grown in monolayer culture or subjected to flow cytometry analysis of 
CSC marker expression. The PBS treated xenograft cells have a more mesenchymal-like 
phenotype with elongated morphology and reduced cell-cell contact, a phenotype typical of 
breast CSCs [46], whereas the imetelstat treated xenograft cells have more epithelial 
morphologic features, namely rounder with more cell-cell contact (Fig. S4c). Furthermore, 
there is a trend of decreased CSC marker expression in imetelstat treated xenograft cells 
compared to vehicle control, but this decrease was not statistically significant due to higher 
variability in the PBS group and small sample size (Fig. S4d). These data suggest imetelstat 
can target the CSC population in vivo.
DISCUSSION
Here, we show HER2+ CSCs have active telomerase that can be inhibited by imetelstat 
treatment, leading to telomere shortening. Imetelstat treatment alone, and in combination 
with trastuzumab, decreased the number of CSCs, as well as their functional ability, as 
shown by decreased mammosphere count and invasive potential. We report the first in vivo 
study of imetelstat and trastuzumab combination, in which the combination treatment has a 
slower tumor growth rate than either drug alone. Additionally, we found a trend toward 
lower CSC marker expression in imetelstat treated xenograft cells compared to PBS control 
using a Triple Negative breast cancer cell line. This study is the first to propose the 
decreased metastases and invasion following imetelstat treatment are due to decreased 
CSCs. Moreover, we are the first to investigate the effect of imetelstat and trastuzumab 
combination therapy on the CSC population.
Interestingly, we observed a decrease in the CSC population following imetelstat treatment 
both prior to shortening of average telomere length and after telomere shortening, suggesting 
the effect of imetelstat on the CSC population may occur in telomere length dependent and 
independent mechanisms, as also reported in multiple myeloma [47]. This study suggested 
imetelstat can target the CSC population by impacting essential stem cell pathways during 
stem cell-fate decisions independent of telomere length and that imetelstat modulates CSC 
growth and self-renewal through decreasing telomere length [47]. In our study, the CSC and 
non-CSC populations have similar telomerase activity and average telomere length, 
discounting the possibility that CSCs have shorter baseline telomeres and thus require less 
time to reach critically short lengths. While we did not observe shortening of average 
telomere length after 42 days of treatment in the HCC1569 cells (Fig. S2), imetelstat did 
shorten the longer telomeres at this time point (Fig. 1f). Moreover, it has recently been 
published that 19 day treatment of imetelstat affected telomere size distribution [32]; 
therefore, we cannot distinguish whether the decrease in CSCs, mammospheres, and 
invasive potential after 12 day treatment is due to telomere length dependent or independent 
mechanisms.
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A potential telomere length independent mechanism to explain the effect of imetelstat on 
CSCs could be due to reversal of the epithelial mesenchymal transition (EMT). EMT 
activation is associated with maintenance of stem cell properties and acquisition of invasive 
and metastatic properties; EMT is able to generate CSCs [48,46,49]. We observed a change 
in cellular phenotype of imetelstat treated xenograft cells compared to PBS treated (Fig. 
S4c). EMT is crucial for the initial steps of metastasis; however, cells must then undergo a 
reversion of EMT termed MET to colonize a metastatic lesion [50]. Interestingly, a recent 
study investigated the off-target effects of imetelstat and found imetelstat disrupted the 
cytoskeleton through changes in actin, tubulin, and intermediate filament organization; 
furthermore, imetelstat decreased MMP2 expression and subsequently invasive ability of 
lung cancer cells [51]. Of note, this study also found imetelstat treatment resulted in a loss of 
E-cadherin, which could suggest cells have undergone EMT, but are unable to subsequently 
undergo MET and cannot adhere to colonize a metastatic lesion.
While EMT has been closely associated with CSCs, other studies suggest cells that undergo 
EMT are not the cells responsible for metastases [52]. Studies were carried out by Liu and 
collaborators to better understand the relationship between EMT, MET, and CSCs and 
furthermore distinguish between CD44+/CD24− CSCs and ALDH+ CSCs [53]. The 
researchers found many genes displayed reciprocal expression patterns between CD44+/
CD24− and ALDH+ cell populations. However, a set of transcripts expressed in CD44+/
CD24− and ALDH+ cell populations overlapped with spheroid-forming cells, likely 
representing genes involved in stem cell function. These results suggest two stem cell 
compartments in human breast cancers are identified by CSC markers. Moreover, CD44+/
CD24− CSCs were significantly enriched in EMT- associated genes and ALDH+ CSCs were 
elevated in genes associated with the epithelial-like state [53]. Furthermore, purified CD44+/
CD24− or ALDH+ cells were able to generate heterogeneous populations and recapitulate 
the populations present in the original cell line, suggesting CSCs display plasticity and are 
able to reversibly transition between the mesenchymal-like CD44+/CD24− CSC state and 
the epithelial-like ALDH+ CSC state [53]. This switching between two distinct EMT and 
non-EMT CSC populations is supported by work in squamous cell carcinoma in which 
CSCs behaved likewise [54]. Of note, it may be important to target both CSC populations as 
they can alternate between the two states [53]. Importantly, we show imetelstat alone and in 
combination with trastuzumab decreased CD44+/CD24− and ALDH+ CSCs in a number of 
cell lines and most notably both CSC populations in the HCC1569 cell line.
In summary, our results show imetelstat treatment of HER2+ breast cancer cells leads to 
telomerase inhibition and decreases the CSC population alone and in combination with 
trastuzumab. Markedly, imetelstat and trastuzumab combination is able to decrease the 
percentage of CD44+/CD24− and ALDH+ CSCs in the same cell line, suggesting this 
combination would be effective in targeting CSCs because cells would not benefit from 
transitioning to the other CSC state, which could potentially occur if we were only able to 
target one CSC state. Imetelstat decreased the self-renewal potential as well as invasive 
potential of the CSC population alone and in combination with trastuzumab. CSCs are 
thought to be responsible for recurrent and metastatic disease and our study suggests adding 
imetelstat to trastuzumab treatment may provide a more durable clinical response for HER2+ 
breast cancer patients.
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Fig. 1. 
CSCs have active telomerase that can be inhibited by imetelstat leading to telomere 
shortening. A) Detection of telomerase activity by TRAP assay of HCC1569 flow sorted 
CSCs and non-CSCs by marker expression following 3 day treatment. UT= untreated cells, 
163L= imetelstat treated cells B) Average quantification of relative telomerase activity from 
A) using ratio of telomerase products to internal standard, n = 3 for CD44/CD24 sorting and 
n = 2 for ALDH sorting, p = 0.2344 for UT, p = 0.4720 for sense, p = 0.5872 for 163L (one-
way ANOVA comparing unsorted, CD44+/CD24−, and CD44+/CD24+) C) TRAP assay of 
SKBR3 and HCC1954 flow sorted CSCs and non-CSCs following 4 day treatment. D) 
Average quantification of relative telomerase activity from C), n = 2. E) Telomere length 
determination by Terminal restriction fragment analysis of HCC1569 and HCC1954 flow 
sorted cells following 6 weeks of treatment. MWM= molecular weight marker, Unsort= 
unsorted cells, S= sense oligonucleotide control, HCC1569 CSC= CD44+/CD24−, HCC1569 
non-CSC= CD44+/CD24+, HCC1954 CSC= ALDH+, HCC1954 non-CSC= ALDH− . F) 
Telomere length quantification using TELORUN of sorted HCC1569 (left panels) and 
HCC1954 (right panels) cells pretreated with imetelstat or untreated for 6 weeks prior to 
sorting CSC (top panels) and non-CSC (bottom panels) populations. Shift in Molecular 
Weight (telomere length in Kb) after imetelstat treatment (red lines) shows telomere 
shortening of the longer telomeres within each sample. a.u. = arbitrary units.
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Fig. 2. 
Imetelstat but not the sense oligonucleotide control decreases the CSC population and 
mammosphere counts. A) Scatter plot of CSC marker expression following treatment. B) 
Flow cytometry analysis of CSC marker expression. C) Representative images of 
mammosphere cultures following pretreatment. D) Primary mammosphere count grouped by 
mammosphere size (n=3), average ± SD, one-way ANOVA, * p<0.05, ** p< 0.01 compared 
to untreated. E) Sum of mammosphere size groups as total mammosphere count, average ± 
SD, ANOVA, * p< 0.05 compared to untreated.
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Fig. 3. 
Imetelstat augments the effects of trastuzumab in HER2+ breast cancer cells. A) 
Representative dose-response curve for HCC1569 cells treated with imetelstat, trastuzumab, 
or 1:8 combination for 5 days. B) Average IC50 values of each drug as a single agent or in 
combination, Average + SD, n = 4, p = 0.0055 for imetelstat, p = 0.0470 for trastuzumab 
(Student’s t-test). C) Representative dose-response curve for HCC1954 cells treated with 
imetelstat, trastuzumab, or 1:4 combination for 5 days. D) Average IC50 values of each drug 
as a single agent or in combination, Average + SD, n = 5, p = 0.0107 for imetelstat, p = 
0.0058 for trastuzumab (Student’s t-test). * = p < 0.05, ** = p < 0.01.
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Fig. 4. 
Imetelstat and trastuzumab combination treatment decreases CSCs. A) CSC marker 
expression of HCC1569 cells analyzed by flow cytometry. Average percent CD44+/CD24− 
+ SD, n=3, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to untreated 
B) ALDH enzymatic activity of HCC1569 cells measured by flow cytometry. Average 
percent ALDH+ + SD when error bars are shown, n=3, one-way ANOVA, * p < 0.05, ** p < 
0.01 compared to untreated C) ALDH enzymatic activity of HCC1954, SKBR3, and 
SKBR3-R cells measured by flow cytometry after 6 days of treatment. Average percent 
ALDH+ + SD, n=3
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Fig. 5. 
Imetelstat and trastuzumab combination treatment inhibits mammosphere formation and 
invasive potential. A) Total mammosphere counts from 12 and 90 day pretreatment 
HCC1569 mammosphere cultures, Average ± SD, n=3, one-way ANOVA, * p < 0.05, ** p 
< 0.01, *** p < 0.001 compared to untreated. B) Representative Images of Primary 
Mammospheres cultured from HCC1569 cells, 4X Magnification, 200 µm scale bar. C) 
Representative images of invaded cells in purple, 10X magnification, 60 µm scale bar. D) 
Invaded cells in 10 random fields per well, Average ± SD, n=3, one-way ANOVA, ** p < 
0.01 compared to untreated
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Fig. 6. 
Imetelstat, trastuzumab, and combination treatment decrease primary tumor growth in vivo. 
A) Tumor volume of HCC1954 cells by caliper measurements in PBS control (thrice 
weekly, n=9), trastuzumab (20 mg/kg twice weekly, n=10), imetelstat (30 mg/kg, thrice 
weekly, n=10), and combination (trastuzumab twice weekly and imetelstat thrice weekly, 
n=9) treated NSG mice. Average ± SEM B) Rate of tumor growth calculated from A) is the 
slope of line of the average tumor volume over time for each treatment group
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Table 1
Combination Index Values for Trastuzumab and Imetelstat Combination Treatment
Cell Line
[Imetelstat]
(μM)
[Trastuzumab]
(μM)
Combination
Index
HCC1569 0.156 0.020 0.466
0.313 0.039 0.908
0.625 0.078 0.554
1.25 0.156 0.334
2.5 0.313 0.295
5 0.625 0.313
10 1.25 1.148
20 2.5 9.013
40 5 0.327
80 10 0.060
HCC1954 0.156 0.039 0.137
0.313 0.078 0.228
0.625 0.156 0.322
1.25 0.313 0.654
2.5 0.625 1.136
5 1.25 1.343
10 2.5 1.301
20 5 0.823
40 10 0.723
80 20 0.917
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